vs
HAEMONETICS CORP（HAE）与Rocket Lab Corp（RKLB）财务数据对比。点击上方公司名可切换其他公司
HAEMONETICS CORP的季度营收约是Rocket Lab Corp的1.9倍（$339.0M vs $179.7M），HAEMONETICS CORP净利率更高（13.2% vs -29.5%，领先42.7%），Rocket Lab Corp同比增速更快（35.7% vs -2.7%），HAEMONETICS CORP自由现金流更多（$87.2M vs $-114.2M），过去两年Rocket Lab Corp的营收复合增速更高（39.2% vs 0.4%）
豪洛捷（Haemonetics）是全球血液与血浆供应及服务提供商，于20世纪70年代由艾伦·（杰克）·莱瑟姆博士在马萨诸塞州内蒂克创立，业务围绕血液相关产品及配套服务展开，为全球医疗领域提供血液管理相关的专业解决方案。
Rocket Lab是公开上市的航空航天制造商及发射服务提供商，旗下Electron轨道火箭主打小型卫星发射，截至2026年1月已成功完成超75次任务，是全球现役发射次数最多的小型运载火箭。公司还开发了Electron的亚轨道改型HASTE用作高超音速技术测试平台，下一代可复用中型运载火箭Neutron目前也在研发中。
HAE vs RKLB — 直观对比
营收规模更大
HAE
是对方的1.9倍
$179.7M
营收增速更快
RKLB
高出38.4%
-2.7%
净利率更高
HAE
高出42.7%
-29.5%
自由现金流更多
HAE
多$201.4M
$-114.2M
两年增速更快
RKLB
近两年复合增速
0.4%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $339.0M | $179.7M |
| 净利润 | $44.7M | $-52.9M |
| 毛利率 | 59.7% | 38.0% |
| 营业利润率 | 19.9% | -28.4% |
| 净利率 | 13.2% | -29.5% |
| 营收同比 | -2.7% | 35.7% |
| 净利润同比 | 19.3% | -1.1% |
| 每股收益（稀释后） | $0.95 | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HAERKLB
| Q4 25 | $339.0M | $179.7M | ||
| Q3 25 | $327.3M | $155.1M | ||
| Q2 25 | $321.4M | $144.5M | ||
| Q1 25 | $330.6M | $122.6M | ||
| Q4 24 | $348.5M | $132.4M | ||
| Q3 24 | $345.5M | $104.8M | ||
| Q2 24 | $336.2M | $106.3M | ||
| Q1 24 | — | $92.8M |
净利润HAERKLB
| Q4 25 | $44.7M | $-52.9M | ||
| Q3 25 | $38.7M | $-18.3M | ||
| Q2 25 | $34.0M | $-66.4M | ||
| Q1 25 | $58.0M | $-60.6M | ||
| Q4 24 | $37.5M | $-52.3M | ||
| Q3 24 | $33.8M | $-51.9M | ||
| Q2 24 | $38.4M | $-41.6M | ||
| Q1 24 | — | $-44.3M |
毛利率HAERKLB
| Q4 25 | 59.7% | 38.0% | ||
| Q3 25 | 59.5% | 37.0% | ||
| Q2 25 | 59.8% | 32.1% | ||
| Q1 25 | 58.4% | 28.8% | ||
| Q4 24 | 55.5% | 27.8% | ||
| Q3 24 | 54.2% | 26.7% | ||
| Q2 24 | 52.0% | 25.6% | ||
| Q1 24 | — | 26.1% |
营业利润率HAERKLB
| Q4 25 | 19.9% | -28.4% | ||
| Q3 25 | 17.9% | -38.0% | ||
| Q2 25 | 16.8% | -41.3% | ||
| Q1 25 | 21.6% | -48.3% | ||
| Q4 24 | 16.9% | -38.9% | ||
| Q3 24 | 15.0% | -49.5% | ||
| Q2 24 | 11.8% | -40.7% | ||
| Q1 24 | — | -46.4% |
净利率HAERKLB
| Q4 25 | 13.2% | -29.5% | ||
| Q3 25 | 11.8% | -11.8% | ||
| Q2 25 | 10.6% | -46.0% | ||
| Q1 25 | 17.5% | -49.5% | ||
| Q4 24 | 10.8% | -39.5% | ||
| Q3 24 | 9.8% | -49.6% | ||
| Q2 24 | 11.4% | -39.2% | ||
| Q1 24 | — | -47.7% |
每股收益（稀释后）HAERKLB
| Q4 25 | $0.95 | $-0.09 | ||
| Q3 25 | $0.81 | $-0.03 | ||
| Q2 25 | $0.70 | $-0.13 | ||
| Q1 25 | $1.17 | $-0.12 | ||
| Q4 24 | $0.74 | $-0.11 | ||
| Q3 24 | $0.66 | $-0.10 | ||
| Q2 24 | $0.74 | $-0.08 | ||
| Q1 24 | — | $-0.09 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $363.4M | $1.0B |
| 总债务越低越好 | $1.2B | $152.4M |
| 股东权益账面价值 | $911.5M | $1.7B |
| 总资产 | $2.5B | $2.3B |
| 负债/权益比越低杠杆越低 | 1.34× | 0.09× |
8季度趋势，按日历期对齐
现金及短期投资HAERKLB
| Q4 25 | $363.4M | $1.0B | ||
| Q3 25 | $296.4M | $976.7M | ||
| Q2 25 | $292.9M | $688.1M | ||
| Q1 25 | $306.8M | $428.4M | ||
| Q4 24 | $320.8M | $419.0M | ||
| Q3 24 | $299.3M | $442.4M | ||
| Q2 24 | $344.4M | $496.8M | ||
| Q1 24 | — | $492.5M |
总债务HAERKLB
| Q4 25 | $1.2B | $152.4M | ||
| Q3 25 | $1.2B | $347.0M | ||
| Q2 25 | $1.2B | $346.5M | ||
| Q1 25 | $1.2B | $345.9M | ||
| Q4 24 | — | $345.4M | ||
| Q3 24 | — | $61.2M | ||
| Q2 24 | — | $64.2M | ||
| Q1 24 | — | $66.8M |
股东权益HAERKLB
| Q4 25 | $911.5M | $1.7B | ||
| Q3 25 | $849.2M | $1.3B | ||
| Q2 25 | $882.3M | $688.5M | ||
| Q1 25 | $820.8M | $431.3M | ||
| Q4 24 | $906.9M | $382.5M | ||
| Q3 24 | $878.9M | $419.8M | ||
| Q2 24 | $905.4M | $455.2M | ||
| Q1 24 | — | $478.9M |
总资产HAERKLB
| Q4 25 | $2.5B | $2.3B | ||
| Q3 25 | $2.4B | $2.2B | ||
| Q2 25 | $2.5B | $1.6B | ||
| Q1 25 | $2.5B | $1.3B | ||
| Q4 24 | $2.5B | $1.2B | ||
| Q3 24 | $2.5B | $1.2B | ||
| Q2 24 | $2.5B | $1.2B | ||
| Q1 24 | — | $1.2B |
负债/权益比HAERKLB
| Q4 25 | 1.34× | 0.09× | ||
| Q3 25 | 1.44× | 0.27× | ||
| Q2 25 | 1.39× | 0.50× | ||
| Q1 25 | 1.49× | 0.80× | ||
| Q4 24 | — | 0.90× | ||
| Q3 24 | — | 0.15× | ||
| Q2 24 | — | 0.14× | ||
| Q1 24 | — | 0.14× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $93.6M | $-64.5M |
| 自由现金流经营现金流 - 资本支出 | $87.2M | $-114.2M |
| 自由现金流率自由现金流/营收 | 25.7% | -63.6% |
| 资本支出强度资本支出/营收 | 1.9% | 27.6% |
| 现金转化率经营现金流/净利润 | 2.09× | — |
| 过去12个月自由现金流最近4个季度 | $308.1M | $-321.8M |
8季度趋势，按日历期对齐
经营现金流HAERKLB
| Q4 25 | $93.6M | $-64.5M | ||
| Q3 25 | $111.3M | $-23.5M | ||
| Q2 25 | $17.4M | $-23.2M | ||
| Q1 25 | $116.6M | $-54.2M | ||
| Q4 24 | $43.8M | $-2.4M | ||
| Q3 24 | $48.8M | $-30.9M | ||
| Q2 24 | $-27.4M | $-13.0M | ||
| Q1 24 | — | $-2.6M |
自由现金流HAERKLB
| Q4 25 | $87.2M | $-114.2M | ||
| Q3 25 | $106.3M | $-69.4M | ||
| Q2 25 | $13.6M | $-55.3M | ||
| Q1 25 | $100.9M | $-82.9M | ||
| Q4 24 | $35.2M | $-23.9M | ||
| Q3 24 | $39.4M | $-41.9M | ||
| Q2 24 | $-33.1M | $-28.3M | ||
| Q1 24 | — | $-21.8M |
自由现金流率HAERKLB
| Q4 25 | 25.7% | -63.6% | ||
| Q3 25 | 32.5% | -44.8% | ||
| Q2 25 | 4.2% | -38.3% | ||
| Q1 25 | 30.5% | -67.6% | ||
| Q4 24 | 10.1% | -18.1% | ||
| Q3 24 | 11.4% | -40.0% | ||
| Q2 24 | -9.8% | -26.7% | ||
| Q1 24 | — | -23.5% |
资本支出强度HAERKLB
| Q4 25 | 1.9% | 27.6% | ||
| Q3 25 | 1.5% | 29.6% | ||
| Q2 25 | 1.2% | 22.2% | ||
| Q1 25 | 4.7% | 23.4% | ||
| Q4 24 | 2.5% | 16.3% | ||
| Q3 24 | 2.7% | 10.5% | ||
| Q2 24 | 1.7% | 14.4% | ||
| Q1 24 | — | 20.7% |
现金转化率HAERKLB
| Q4 25 | 2.09× | — | ||
| Q3 25 | 2.88× | — | ||
| Q2 25 | 0.51× | — | ||
| Q1 25 | 2.01× | — | ||
| Q4 24 | 1.17× | — | ||
| Q3 24 | 1.44× | — | ||
| Q2 24 | -0.71× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HAE
| Hospital | $143.5M | 42% |
| Plasma Productsand Services | $138.9M | 41% |
| Blood Center Productsand Services | $56.6M | 17% |
RKLB
| Products | $94.0M | 52% |
| Transferred Over Time | $87.3M | 49% |
